{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T22:48:43Z","timestamp":1776984523829,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00710","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T04:35:50Z","timestamp":1589862950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China"],"prefix":"10.3389","volume":"11","author":[{"given":"Huan","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvere D.","family":"Zaongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry","volume":"49","author":"Berg","year":"2019","journal-title":"Aliment Pharmacol. Ther."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007885","article-title":"Current treatment status and barriers for patients with chronic HCV infection in mainland China: A national multicenter cross-sectional survey in 56 hospitals","volume":"96","author":"Bian","year":"2017","journal-title":"Med. (Baltimore)"},{"key":"B3","unstructured":"BureauT.M.H.R.A.S.S.\n          2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1038\/emi.2017.77","article-title":"Hepatitis C virus genotypes and subtypes circulating in Mainland China","volume":"6","author":"Chen","year":"2017","journal-title":"Emerg. Microbes Infect."},{"key":"B5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL Recommendations on Treatment of Hepatitis C 2018","volume":"69","year":"2018","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"Feld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/liv.13293","article-title":"Hepatitis C: efficacy and safety in real life","author":"Flisiak","year":"2017","journal-title":"Liver Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B9","unstructured":"Cancer Therapy Evaluation Program CTCAE V5.02017"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2018.09.005","article-title":"Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data","volume-title":"J. Microbiol. Immunol. Infect.","author":"Hong","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3908767","article-title":"Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China","volume":"2018","author":"Hu","year":"2018","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jmv.25454","article-title":"Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection","volume":"91","author":"Huang","year":"2019","journal-title":"J. Med. Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","article-title":"Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1","volume":"52","author":"Iio","year":"2017","journal-title":"J. Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/hepr.13256","article-title":"Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study","volume":"49","author":"Itokawa","year":"2019","journal-title":"Hepatol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/apt.14507","article-title":"Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia","volume":"47","author":"Ji","year":"2018","journal-title":"Aliment Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","article-title":"Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis","volume":"67","author":"Kwo","year":"2017","journal-title":"J. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1002\/hep.29130","article-title":"Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus","volume":"65","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s12072-018-9891-9","article-title":"Tolerable and curable treatment in HIV\/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China","volume":"12","author":"Li","year":"2018","journal-title":"Hepatol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/jvh.12938","article-title":"The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: An observational population-based study","volume":"25","author":"Liu","year":"2018","journal-title":"J. Viral. Hepat."},{"key":"B20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","article-title":"Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil","volume":"18","author":"Lobato","year":"2019","journal-title":"Ann. Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/14787210.2019.1676730","article-title":"Developments in the treatment of HCV genotype 3 infection","volume":"17","author":"McPhee","year":"2019","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz128","article-title":"Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian\/Alaskan Natives","volume":"6","author":"Mera","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol. Int."},{"key":"B25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.29258","article-title":"Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study","volume":"66","author":"Saxena","year":"2017","journal-title":"Hepatology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12072-018-9872-z","article-title":"Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan","volume":"12","author":"Suzuki","year":"2018","journal-title":"Hepatol. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1053\/j.gastro.2014.03.008","article-title":"Impact of new hepatitis C treatments in different regions of the world","author":"Wei","year":"2014","journal-title":"Gastroenterology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1111\/jgh.14102","article-title":"Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China","volume":"33","author":"Wei","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s12072-018-9856-z","article-title":"Ledipasvir\/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study","volume":"12","author":"Wei","year":"2018","journal-title":"Hepatol. Int."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","article-title":"Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study","volume":"66","author":"Zeng","year":"2017","journal-title":"J. Hepatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12879-019-4217-7","article-title":"Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Infect. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00710\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T04:35:53Z","timestamp":1589862953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00710\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":32,"alternative-id":["10.3389\/fphar.2020.00710"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00710","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"article-number":"710"}}